<DOC>
	<DOCNO>NCT00239031</DOCNO>
	<brief_summary>All patient core study interested treat EC-MPS include open-label extension study collect information long-term safety , tolerability efficacy drug . The aim study compare renal function , 6 month transplant , de novo old-age renal transplant recipient treat EC-MPS plus reduce dose CsA-ME EC-MPS plus standard dose CsA-ME , combination basiliximab short-term oral steroid .</brief_summary>
	<brief_title>Study Enteric-Coated Mycophenolate Sodium ( EC-MPS ) Plus Reduced-dose Cyclosporine Microemulsion ( CsA-ME ) Compared EC-MPS Plus Standard Dose CsA-ME Eldery de Novo Renal Transplant Recipients Treated With Basiliximab Short-term Steroids</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion Male female patient 55_75 year old , recipient primary kidney transplant cadaver donor Subjects CsAME plus basiliximab select basic immunosuppressive regimen . Cold ischemia time 20 hr . Females childbearing potential must negative serum pregnancy test within 7 day prior enrollment must use effective contraception trial 6 week follow discontinuation study medication . Patients willing able participate full course study write informed consent obtain . Exclusion criterion Multiorgan recipient ( e.g . kidney pancreas , double kidney ) previous transplant . Patients know hypersensitivity mycophenolic acid component formulation ( e.g . lactose ) . Patients thrombocytopenia ( 75,000 mm ) , absolute neutrophil count 1,500 mm leukocytopenia ( 2,500 mm3 ) and/or hemoglobin &lt; 6 g/dL Screening Baseline . Patients receive investigational drug within four week prior study entry . Patients history malignancy within last five year , except excise squamous basal cell carcinoma skin . Females childbearing potential planning become pregnant , pregnant lactating , unwilling use effective mean contraception . Presence clinically significant infection require continued therapy . Known positivity HIV positive HBsAg test . Evidence drug alcohol abuse Existence surgical medical condition , current transplant , opinion investigator might significantly alter absorption , distribution , metabolism excretion study medication , and/or presence severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus . Patients Panel Reactive Antibodies ( PRA ) historical peak evaluation 30 % recent evaluation 15 % .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Renal transplantation , EC-MPS</keyword>
</DOC>